Zentalis Pharmaceuticals
ZNTL
128 hedge funds and large institutions have $188M invested in Zentalis Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 32 reducing their positions, and 13 closing their positions.
641% more capital inflows, than outflows
Capital inflows: $94.1M | Capital outflows: $12.7M
167% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $484K
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
41% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 32
27.84% more ownership
Funds ownership: 66.78% → 94.62% (+28%)
10% more funds holding
Funds holding: 116 → 128 (+12)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NEA Management Company
Timonium,
Maryland
|
+$14.4M |
| 2 |
Squadron Capital Management
Westmont,
Illinois
|
+$12.6M |
| 3 |
ADAR1 Capital Management
Austin,
Texas
|
+$12.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.84M |
| 5 |
Patient Square Capital
Menlo Park,
California
|
+$8.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$1.12M |
| 2 |
Morgan Stanley
New York
|
-$1.08M |
| 3 |
Peapod Lane Capital
Bedford Hills,
New York
|
-$984K |
| 4 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$983K |
| 5 |
Two Sigma Investments
New York
|
-$902K |
ZNTL Hedge Fund Activity: Q3 2026 in Review
128 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2026, worth a combined $188M — down 18% from $230M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ZNTL positions and 13 closed out — a net gain of 13 holders — while 45 added to existing stakes and 32 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $14.4M. The largest seller was D.E. Shaw & Co, cutting an estimated $1.12M.
- 128 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2026, up from 116 in Q2 2026.
- Funds reported $188M of Zentalis Pharmaceuticals stock for Q3 2026, down 18% quarter-over-quarter.
- 26 funds opened new Zentalis Pharmaceuticals positions in Q3 2026 and 13 closed out, a net change of +13 holders.
- The largest Zentalis Pharmaceuticals buyer in Q3 2026 was NEA Management Company, an estimated $14.4M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2026 was D.E. Shaw & Co, an estimated $1.12M sold.
Based on aggregated 13F filings for Q3 2026.